首页> 美国卫生研究院文献>British Medical Journal >In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.
【2h】

In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.

机译:甲状腺毒性周期性麻痹患者的体内和体外钠泵活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE--To examine whether sodium pump activity plays a part in the pathogenesis of thyrotoxic periodic paralysis. DESIGN--Measurement of platelet sodium-potassium ATPase and in vivo sodium pump activities in healthy subjects and thyrotoxic subjects with and without paralysis. SETTING--University hospital in Hong Kong. SUBJECTS--21 healthy subjects, 23 untreated thyrotoxic subjects, 13 untreated men with periodic paralysis, seven treated thyrotoxic subjects, and six treated men with periodic paralysis. MAIN OUTCOME MEASURES--Platelet Na+, K(+)-ATPase activity and plasma rubidium concentration after oral loading. RESULTS--Median (range) platelet Na+, K(+)-ATPase activity in thyrotoxic subjects was 253 (169-821) mumol inorganic phosphate/h/g protein--significantly higher than that in healthy subjects (134 (81-180) mumol/h/g protein; p less than 0.001). Na+, K(+)-ATPase activity in those with periodic paralysis was 374 (195-1196) mumol/h/g protein, again significantly higher than that in healthy subjects (p less than 0.001) and that in other thyrotoxic subjects (p less than 0.01) despite similar degrees of hyperthyroidism. Activities in treated thyrotoxic subjects with and without periodic paralysis were 148 (110-234) and 131 (86-173) mumol/h/g protein respectively. Mean (95% confidence interval) plasma rubidium concentration five hours after oral administration in thyrotoxic subjects (7.0 (6.6 to 7.5) mumol/l) was significantly lower than in healthy subjects (10.2 (9.5 to 10.9) mumol/l; p less than 0.001) and higher than in those with periodic paralysis (6.0 (5.7 to 6.3) mumol/l; p less than 0.01). CONCLUSIONS--Sodium pump activity in untreated subjects with periodic paralysis is higher than in other thyrotoxic subjects, and this may be responsible for the hypokalaemia.
机译:目的-检查钠泵的活性是否在甲状腺毒性周期性麻痹的发病机理中起作用。设计-在患有和不患有麻痹的健康受试者和甲状腺毒性受试者中测量血小板钠钾ATP酶和体内钠泵活性。地点-香港大学医院。主题--21健康受试者,23名未经治疗的甲状腺毒性受试者,13名未经治疗的周期性麻痹男性,7名经过治疗的甲状腺毒性受试者和6名经治疗的周期性麻痹男性。主要观察指标-口服负荷后血小板的Na +,K(+)-ATPase活性和血浆rub浓度。结果-在甲状腺毒性受试者中,血小板Na +,K(+)-ATPase活性的中位数(范围)为253(169-821)μmol无机磷酸盐/ h / g蛋白-显着高于健康受试者(134(81-180) )mumol / h / g蛋白质; p小于0.001)。周期性麻痹患者的Na +,K(+)-ATPase活性为374(195-1196)mumol / h / g蛋白,再次显着高于健康受试者(p小于0.001)和其他甲状腺毒性受试者(p小于0.01),尽管甲亢程度相似。在有和没有周期性麻痹的经治疗的甲状腺毒性受试者中,其活性分别为148(110-234)和131(86-173)mumol / h / g蛋白。甲状腺毒性受试者口服后五小时的平均(浓度(95%置信区间)血浆(浓度(7.0(6.6至7.5)μmol/ l)显着低于健康受试者(10.2(9.5至10.9)μmol/ l; p小于0.001),高于周期性麻痹的患者(6.0(5.7至6.3)mumol / l; p小于0.01)。结论-周期性瘫痪的未经治疗的受试者的钠泵活性高于其他甲状腺毒性受试者,这可能是低钾血症的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号